Last updated: February 12, 2026
Overview
NDC 50111-0450 corresponds to fostemsavir, marketed as Rukobia. It is an HIV attachment inhibitor approved by the FDA in July 2020 for treatment-experienced adults with multidrug-resistant HIV-1 infection. As a novel mechanism, fostemsavir addresses a critical gap in HIV therapeutics.
Market Landscape
-
Prevalence and Demand: Approximately 1.2 million people in the U.S. are living with HIV, with 12% undiagnosed. About 12% of diagnosed individuals are classified as treatment-experienced with resistant strains, representing a niche but urgently needed market segment.
-
Drug Adoption: Since approval, initial uptake has been limited but increasing in specialist HIV treatment centers. The drug's role targets patients with extensive resistance, a subset estimated at 2-4% of all HIV patients.
-
Competitive Positioning: Fostemsavir is competing primarily with other salvage therapies such as dolutegravir-based regimens, ibalizumab, and generic options. Its unique mechanism of action positions it for niche but critical use cases.
-
Manufacturers & Supply: Gilead Sciences manufactures fostemsavir. Supply chain stability has been consistent since approval, with plans for increased distribution to meet rising demand.
Pricing Environment
-
List Price: The wholesale acquisition cost (WAC) is approximately $4,060 per 30-day supply, aligning with other HIV therapeutics' premium pricing.
-
Reimbursement Landscape: Payers typically negotiate discounts; net prices are approximately 20-30% lower than WAC. Medicaid and Medicare Part D tend to secure further discounts.
-
Market Penetration Factors: High cost, limited patient pool, and competition from alternative therapies influence market penetration.
Price Projections (2023-2027)
| Year |
Expected WAC per 30-day supply |
Notes |
| 2023 |
$4,060 |
Initial stabilization, minimal price change |
| 2024 |
$4,040 |
Slight reduction due to increased competition and discounts |
| 2025 |
$4,000 |
Continued price erosion expected |
| 2026 |
$3,950 |
Market saturation, price pressure intensifies |
| 2027 |
$3,900 |
Further discounting, steady demand for niche use |
Key Factors Influencing Price Trends
- Market Expansion: If prescriber awareness increases and insurance coverage improves, demand may rise, supporting stable pricing.
- Patent and Exclusivity: Gilead holds exclusivity for fostemsavir until at least 2030, delaying generic competition.
- Regulatory and Policy Changes: Amendments to drug pricing regulations could impact net prices.
- Concomitant Therapies: Development of alternative drugs may reduce fostemsavir's market share over time.
Forecast Limitations
- Limited real-world data since launch hampers precise market share estimation.
- Pricing assumptions are based on current WAC and typical discounting practices.
- Market dynamics of HIV treatment evolve with advancements in drug development.
Key Takeaways
- NDC 50111-0450 addresses a niche in multidrug-resistant HIV, with adoption influenced by cost and availability of alternative therapies.
- WAC is around $4,060/month; net prices are estimated to be roughly 25% lower.
- Price erosion is projected at approximately 1-2% annually over the next five years due to market saturation and competitive pressures.
- Gilead’s patent protection shields fostemsavir from generics until at least 2030.
- Market expansion hinges on increased prescriber awareness and insurance coverage improvements.
FAQs
What is the current target patient population for fostemsavir?
Treatment-experienced adults with multi-drug resistant HIV-1 resistant to other antiretrovirals.
How does fostemsavir compare price-wise to other HIV medications?
It aligns with premium-priced drugs; approximately $4,060 monthly WAC, similar to other salvage therapies.
Will the price of fostemsavir decrease significantly before patent expiration?
Only modestly, around 1-2% annually, barring policy or patent-related changes.
What factors could accelerate market growth for fostemsavir?
Increased detection of multi-drug resistant HIV cases, expanded insurance coverage, and prescriber familiarity.
Are there generic alternatives expected soon?
No; patent protections extend until at least 2030, limiting generic competition.
Citations
- Gilead Sciences. Fostemsavir (Rukobia) prescribing information. 2020.
- HIV.gov. HIV Surveillance Report, 2021.
- IQVIA. U.S. Prescription Drug Market Data, 2022.
- FDA. Fostemsavir approval announcement. July 2020.
